|Animal Health Trust, Newmarket, England.
AHT is an independent trust working within animal health since more than 50 years and has more than 200 employees, including research staff and clinicians. AHT is one of the few institutions in Europe where experimental infections classified as high risk to the environment can be performed. At the Allen Centre facility, Intervacc has tested its prototype vaccines in horses.
|Moredun Scientific, Edinburgh, Skottland.
Our cooperating partner in the Eurostars-2 funded project for further development of a vaccine against infection of piglets caused by Streptococcus suis. Moredun Scientific is a contract research organisation specialising in animal health and biosafety testing of biopharmaceuticals.
|The Swedish University of Agricultural Sciences (SLU), Uppsala.
SLU, the Swedish University of Agricultural Sciences, is one of our partners for the development of a new generation of animal health vaccines using recombinant proteins. SLU is a world-class international university with research, education and environmental assessment within the sciences for sustainable life.
|Karolinska Institute, KI, Stockholm.
Karolinska Institutet, KI is one of our partners for the development of a new generation of animal health vaccines using recombinant proteins. KI is one of the world’s foremost medical universities including both research and education with a vision is to advance knowledge about life and strive towards better health for all.
|3P Biopharmaceuticals, Pamplona, Spain
3P Biopharmaceuticals is our partner for contract manufacturing of Strangvac®, Intervacc´s recombinant vaccine against strangles. The collaboration between the Companies covers transfer of the manufacturing technology, production of validation batches and long term future commercial manufacturing.
|PX´Therapeutics, Grenoble, Frankrike
PX'Therapeutics, a subsidiary of Aguettant pharmaceuticals, has been engaged by Intervacc to streamline the production process of Strangvac® for commercial large-scale GMP manufacturing. The business group has the experience, equipment and staff to optimize processes to produce recombinant E. coli proteins.
Analyses of Strangvac® for stability studies
|Novavax AB, Uppsala
Novavax have developed a patented technology that enhances the effect of vaccines (adjuvants). The technique is based on different immune-stimulating components, saponins, which are extracted from the tree Quillaja saponaria. Following purification the immune-stimulating components produce different complexes named iscomes. Iscomes are included in several authorised vaccines amongst one of which is a vaccine against horse influensa. Intervacc has an agreement with Novavax to use the iscome technology in its strangles vaccine.
|Sofus Regulatory Affairs, Stockholm
|AWA Patent, Stockholm
|Ernst & Young, Stockholm
Financial and strategic advisory